CA2944210C - Crystalline forms - Google Patents

Crystalline forms Download PDF

Info

Publication number
CA2944210C
CA2944210C CA2944210A CA2944210A CA2944210C CA 2944210 C CA2944210 C CA 2944210C CA 2944210 A CA2944210 A CA 2944210A CA 2944210 A CA2944210 A CA 2944210A CA 2944210 C CA2944210 C CA 2944210C
Authority
CA
Canada
Prior art keywords
degrees
polymorph
theta
diffraction pattern
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944210A
Other languages
English (en)
French (fr)
Other versions
CA2944210A1 (en
Inventor
David Paul CHILDS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shield Tx UK Ltd
Original Assignee
Shield Tx UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2944210(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shield Tx UK Ltd filed Critical Shield Tx UK Ltd
Publication of CA2944210A1 publication Critical patent/CA2944210A1/en
Application granted granted Critical
Publication of CA2944210C publication Critical patent/CA2944210C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
CA2944210A 2014-10-28 2015-10-23 Crystalline forms Active CA2944210C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1419174.6 2014-10-28
GB1419174.6A GB2531742B (en) 2014-10-28 2014-10-28 Polymorphs of ferric maltol
PCT/EP2015/074653 WO2016066555A1 (en) 2014-10-28 2015-10-23 Crystalline forms of ferric maltol

Publications (2)

Publication Number Publication Date
CA2944210A1 CA2944210A1 (en) 2016-05-06
CA2944210C true CA2944210C (en) 2017-06-20

Family

ID=52103522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944210A Active CA2944210C (en) 2014-10-28 2015-10-23 Crystalline forms

Country Status (18)

Country Link
US (1) US9802973B2 (enExample)
EP (1) EP3160951B1 (enExample)
JP (2) JP6404358B2 (enExample)
KR (1) KR102576930B1 (enExample)
CN (1) CN107001310B (enExample)
AU (1) AU2015340825B2 (enExample)
CA (1) CA2944210C (enExample)
CL (1) CL2017001030A1 (enExample)
EA (1) EA033323B1 (enExample)
ES (1) ES2661944T3 (enExample)
GB (1) GB2531742B (enExample)
IL (1) IL251863A0 (enExample)
MX (1) MX370730B (enExample)
PL (1) PL3160951T3 (enExample)
SA (1) SA517381406B1 (enExample)
SG (1) SG11201702639RA (enExample)
WO (1) WO2016066555A1 (enExample)
ZA (1) ZA201702136B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
CN112574158B (zh) * 2020-12-29 2022-08-02 南京百泽医药科技有限公司 一种麦芽酚铁晶型ii及其制备方法
IT202100018578A1 (it) 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
AU2022349859A1 (en) * 2021-09-21 2024-05-02 Apicore Pharmaceuticals Private Limited An improved process for the preparation of ferric maltol
CN119638662B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-草酸共晶及其制备方法
CN119638661B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-槲皮素共晶及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8410290D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
GB0211500D0 (en) * 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
GB201101370D0 (en) * 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol

Also Published As

Publication number Publication date
CL2017001030A1 (es) 2018-01-19
EP3160951B1 (en) 2017-12-06
JP6404358B2 (ja) 2018-10-10
KR102576930B1 (ko) 2023-09-12
AU2015340825B2 (en) 2016-11-24
IL251863A0 (en) 2017-06-29
KR20170071446A (ko) 2017-06-23
GB201419174D0 (en) 2014-12-10
SA517381406B1 (ar) 2021-03-15
CA2944210A1 (en) 2016-05-06
CN107001310A (zh) 2017-08-01
ZA201702136B (en) 2018-11-28
WO2016066555A1 (en) 2016-05-06
US9802973B2 (en) 2017-10-31
CN107001310B (zh) 2020-05-22
JP2018197268A (ja) 2018-12-13
BR112017008903A2 (pt) 2017-12-19
JP6678711B2 (ja) 2020-04-08
EA201790667A1 (ru) 2017-08-31
PL3160951T3 (pl) 2018-07-31
JP2017535510A (ja) 2017-11-30
GB2531742A (en) 2016-05-04
ES2661944T3 (es) 2018-04-04
AU2015340825A1 (en) 2016-08-25
MX370730B (es) 2019-12-20
MX2017005413A (es) 2017-10-04
EA033323B1 (ru) 2019-09-30
EP3160951A1 (en) 2017-05-03
GB2531742B (en) 2016-10-05
US20170260222A1 (en) 2017-09-14
SG11201702639RA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CA2944210C (en) Crystalline forms
JP6206689B2 (ja) ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉを含有する医薬製剤
AU2024203511A1 (en) Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof
WO2015109445A1 (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
JP2014051517A (ja) デフェラシロックス（ｉｃｌ６７０ａ）の多形形態
EP1364959B1 (en) Crystal of pyrimidine nucleoside derivative
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
KR20220148860A (ko) 2-[(4s)-8-플루오로-2-[4-(3-메톡시페닐)피페라진-1-일]-3-[2-메톡시-5-(트리플루오로메틸)페닐]-4h-퀴나졸린-4-일]아세트산의 칼륨 염
SK281980B6 (sk) Kryštallický (+)l-hydrogenvínan, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom a jeho použitie
HK1233619A1 (en) Crystalline forms of ferric maltol
HK1233619B (en) Crystalline forms of ferric maltol
US9593116B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
BR112017008903B1 (pt) Formas cristalinas de maltol férrico
HK1223929B (zh) 5-氨基-2，3-二氢-(2，3-二氮杂萘)-1，4-二酮钠盐的晶型

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161003

EEER Examination request

Effective date: 20161003